PRECISION is the first randomized clinical trial to demonstrate the value of an adjunctive test for men with elevated prostate-specific antigen (PSA) level. Multiparametric magnetic resonance imaging (mp-MRI) and MRI-ultrasound fusion targeted biopsy of suspicious lesions was reported to improve both the sensitivity and specificity of PSA testing, with fewer biopsies conducted but more high-grade cancers diagnosed in patients randomized to MRI compared with standard systematic prostate biopsy.1
Kim SJ, Vickers AJ, Hu JC. Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening. JAMA Oncol. 2018;4(12):1663–1664. doi:10.1001/jamaoncol.2018.4160
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.